- Home
- PNR vs RPRX Comparison
PNR vs RPRX Comparison
Compare PNR & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PNR | RPRX |
|---|---|---|
| Founded | 1966 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1B | 16.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PNR | RPRX |
|---|---|---|
| Price | $104.32 | $39.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $118.23 | $46.00 |
| AVG Volume (30 Days) | 1.2M | ★ 4.3M |
| Earning Date | 10-21-2025 | 11-05-2025 |
| Dividend Yield | 0.96% | ★ 2.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.93 | 1.75 |
| Revenue | ★ $4,128,399,999.00 | $2,349,844,000.00 |
| Revenue This Year | $2.97 | $37.13 |
| Revenue Next Year | $4.64 | $1.48 |
| P/E Ratio | $26.53 | ★ $22.68 |
| Revenue Growth | 0.83 | ★ 3.70 |
| 52 Week Low | $74.25 | $24.05 |
| 52 Week High | $113.95 | $41.24 |
Technical Indicators
Market Signals| Indicator | PNR | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 57.50 |
| Support Level | $103.78 | $39.24 |
| Resistance Level | $106.68 | $40.50 |
| Average True Range (ATR) | 2.21 | 0.91 |
| MACD | 0.19 | -0.08 |
| Stochastic Oscillator | 55.46 | 76.02 |
Price Performance
Historical ComparisonAbout PNR Pentair plc.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2024.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.